T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia

S. Kobayashi,1 M. Ito,1 H. Sano,1 K. Mochizuki,1 M. Akaihata,1 T. Waragai,1 Y. Ohara,1 M. Hosoya,2 H. Ohto3 & A. Kikuta1

1Department of Pediatric Oncology, 2Department of Pediatrics, and 3Division of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan

Received 1 April 2014; accepted for publication 11 August 2014

SUMMARY

Background: Despite improvements in first-line therapies, the outcomes of relapsed or refractory childhood acute leukaemia that has not achieved complete remission after relapse, has relapsed after stem cell transplantation (SCT), has primary induction failure and has relapsed with a very unfavourable cytogenetic risk profile, are dismal.

Objectives and Methods: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.

Results: All patients achieved complete engraftment. The median time to reaching an absolute neutrophil count of more than 0.5 × 10^9 L^{-1} was 14 days. Acute graft-vs-host disease (aGVHD) of grades II–IV and III–IV developed in 10 (71%) and 2 (14%) patients, respectively. Treatment-related mortality and relapse occurred in one (7%) patient and six (43%) patients, respectively. Eleven patients were alive and seven of them were disease-free and remission with an acceptable risk of GVHD in paediatric patients with high-risk childhood acute leukaemia.

Conclusion: These findings indicate that T-cell-replete haplo-SCT, with low-dose ATG and PSL, provides sustained remission with an acceptable risk of GVHD in paediatric patients with advanced haematologic malignancies.

Key words: children, graft-vs-leukaemia effect, HLA-haploidentical stem cell transplantation, refractory leukaemia, T-cell-replete haploidentical stem cell transplantation.

INTRODUCTION

The most common type of cancer in patients under the age of 18 is acute leukaemia (McNeil et al., 2002). Although recent years have seen advances and improvements in effective therapies and outcomes, some cases remain persistently difficult to treat. Overall, the 5-year survival rates for patients with acute lymphoblastic leukaemia (ALL) and patients with acute myelogenous leukaemia (AML) are nearly 85% and 50–60%, respectively (Jemal et al., 2008). Among children with relapsed acute leukaemia, 30–50% can be treated successfully with a combination of chemotherapy and allogeneic stem cell transplantation (SCT) (Hijiya et al., 2004; Raetz et al., 2008; Parker et al., 2010; Tallen et al., 2010). Despite these successes, children who fail to attain complete remission after relapse, relapse after an SCT, experience a primary induction failure, or relapse with a very unfavourable cytogenetic risk profile have very poor prognoses (Gaynon, 2005). With this in mind, it is crucial that new therapies and regimens be developed to meet the needs of this vulnerable population.

It is most challenging when a patient experiences a significant number of induction failures, particularly with an early recurrence of the disease. Furthermore, even when remission is achieved in these instances, it is less likely to persist. Gaynon et al. (2006) reported subsequent relapses in up to one-third of these patients within the median time to allogeneic SCT (allo-SCT). Longer-term event-free survival (EFS) rates for this population of high-risk acute leukaemia patients do not exceed 20% (Einsiedel et al., 2005; Gaynon et al., 2006), even with the use of intensive salvage strategies, including allo-SCT. Furthermore, patients with fms-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) positive or other NK-lineage leukaemia also have a very poor prognosis by conventional allo-SCT even if remission is achieved at transplantation (Suzuki et al., 2006; Sengsayadeth et al., 2012).

One form of immunotherapy that has proven to be highly efficacious for haematological malignancies that are primarily attributed to T-cell-mediated responses to human leukocyte...
antigen (HLA) disparities between donors and leukaemic cells is T-cell-replete haploidentical SCT (haplo-SCT) (Kolb, 2008). Severe graft-vs-host disease (GVHD), rejection and a high risk of early death are related to major complications associated with haplo-SCT (Henslee-Downey et al., 1997; Mehta et al., 2004). The high risks of both graft failure and acute GVHD (aGVHD) associated with haplo-SCT have been mitigated in the past by infusing megadoses of purified ex vivo T-cell-depleted CD34+ peripheral blood stem cells (PBSCs) (Aversa et al., 1998, 2005). However, because the patients lost almost all of their T-cells, their immune reconstitution was slow. This led to high incidences of mainly viral and fungal infectious complications and high relapse rates. In recent studies, enabling haplo-SCT with a T-cell-replete graft using a vigorous pre- and post-transplantation pharmacologic GVHD prophylactic regimen has proven to be an encouraging alternative treatment for the patients (Huang, 2008; Chang & Huang, 2012). However, particularly among high-risk groups, the threat of relapse remains, and the treatment can fail.

Previously, we have reported on the safety profile of a GVHD prophylactic regimen consisting of anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate (MTX) and prednisolone (PSL) in T-cell-replete haplo-SCT and demonstrated that haplo-SCT with our GVHD prophylaxis regimen is as feasible as HLA matched unrelated SCT in terms of GVHD and treatment-related mortality (TRM) (Mochizuki et al., 2011). Using a retrospective approach, we assessed this protocol and found that we were able to achieve an optimal graft-vs-leukaemia (GVL) effect on T-cells by performing T-cell-replete haplo-SCT using a myeloablative preconditioning regimen, accompanied by intensive GVHD prophylaxis, including low-dose ATG and steroids. Patients, even those at an advanced stage of the disease, responded to the treatment and relapse rates decreased.

PATIENTS AND METHODS

Between August 2000 and April 2011, 14 consecutive patients with high-risk acute leukaemia underwent peripheral blood SCT from an HLA-haploidentical related donor at Fukushima Medical University Hospital. All patients were with a Karnofsky or Lansky performance score greater than or equal to 50 at transplantation. High-risk acute leukaemia was defined as primary refractory acute leukaemia not in remission or relapse. Those leukaemia are with poor prognostic features such as positivity for the Philadelphia chromosome, mixed lineage leukaemia gene rearrangements, FLT3/ITD and with early relapse ALL (<36 months from initial diagnosis). NK-lineage leukaemia is included because it has a very poor prognosis even after conventional SCT. The institutional review board approved the protocol, and written informed consent was obtained from the patients or their guardians and family donors. Data were analysed on 1 November 2013. The patient characteristics are shown in Table 1. Donors and patients shared one HLA haplotype, but differed in the other haplotype. For donor selection, there should only be at least three or four incompatible HLAs, and we also preferred donors with the best possible health, who have the same blood type, and are not suffering from anaemia. Donors included fathers (nine), mothers (four) and siblings (one). HLA-A, HLA-B, HLA-C and HLA-DRB1 typing was performed by intermediate-resolution DNA typing (Genosearch HLA: Medical & Biological Laboratories Co., Ltd., Nagoya, Japan). HLA disparities in the graft-vs-host directions included four loci mismatches in 10 patients and three loci mismatches in four patients. The median patient age was 7.3 years (range: 0.8–17.9 years). Myeloablative conditioning was administered to 13 patients (total-body-irradiation-based, nine patients; Busulfan-based, four patients), and one patient with organ dysfunction received reduced intensity conditioning. The conditioning regimen of each patient is described in Table 2. Rabbit ATG (Genzyme Japan K. K., Tokyo, Japan) was used to treat 12 patients at a total dose of 2.5 mg kg⁻¹ body weight. GVHD prophylaxis was conducted using tacrolimus, MTX administered in a short term, and PSL. Tacrolimus was started on day −1, and was continuously administered intravenously. The concentration of tacrolimus in peripheral blood was adjusted to be between 7 and 15 ng mL⁻¹. Three or four weeks after transplantation, the route of tacrolimus administration was changed to oral, with the target trough level within the range of 5–10 ng mL⁻¹. MTX (10 mg m⁻²) was administered intravenously on day +1 and was reduced to 7 mg m⁻² on days +3 and +6 after transplantation. PSL was begun on day +0 at an initial dose of 1 mg kg⁻¹ body weight day⁻¹. When there was no sign of aGVHD, from day +29, the PSL dose was tapered every week and was discontinued within 2 or 3 months after transplantation. All patients received granulocyte-colony-stimulating factor (G-CSF) intravenously on day +1 until sustained granulocyte recovery was achieved. Posttransplantation G-CSF was administered to all 14 patients.

The presence of minimal residual disease (MRD) was analysed in bone marrow samples at diagnosis of ALL in patients by using sensitive quantitative real-time reverse transcriptase polymerase chain reaction (RT-qPCR) methods. A tumour specific primer could be obtained in three patients (Patients 5, 8, 10), and MRD was detected in all three patients using a cut-off point of 0.001% at haplo-SCT.

Each patient was isolated in a laminar air-flow room, and standard decontamination procedures were followed. Intravenous immunoglobulin was administered at a minimum dose of 100 mg kg⁻¹ body weight every week until day +100. TMP/SMX was administered for at least 1 year for prophylaxis against Pneumocystis infections. Acyclovir was administered at 10 mg kg⁻¹ body weight for 25 days after transplantation to prevent herpes simplex infections. CMV-pp65 antigen testing of peripheral blood was performed once weekly. After grafting, ganciclovir or foscarnet administration was initiated in patients with CMV antigenemia.

RESULTS

All the patients received G-CSF-mobilised PBSCs. The patients received PBSCs containing a median of 9.5 × 10⁶ (range:
6.3–13.2 × 10^6) CD34+ cells kg^{-1} body weight without T cell depletion. Consequently, a median of 4.36 × 10^9 (range: 1.18–5.84 × 10^9) CD34+ cells kg^{-1} body weight were transfused. All the patients were engrafted with a median time of 14 days (range: 11–15 days) for neutrophil recovery (absolute neutrophil count >0.5 × 10^9 L^{-1}). The platelet recovery to more than 20 × 10^9 L^{-1} was achieved in 13 patients in a median time of 28 days (range: 18–93 days). All the patients who began in non-remission achieved complete remission on day +30 and showed complete donor chimerism by day +30. Acute GVHD occurred in 12 of the 14 patients. Acute GVHD was grade I in two patients, grade II in eight patients and grade III in two patients. Of the two patients with grade III GVHD, one did not receive ATG. The other patient, who had received ATG, improved symptoms of gut GVHD by temporary augmentation with PSL and oral administration of beclomethasone dipropionate (BDP). Chronic GVHD (cGVHD) developed in 11 of 12 evaluable patients. Relapse occurred in six patients (43%) on days +45, +117, +159, +405, +600 and +670. Among the six patients who relapsed, one (Patient 6) received additional chemotherapy, one (Patient 11) received a second haplo-SCT from another haploidentical donor and one (Patient 13) received donor lymphocyte infusion for his bone marrow (BM) relapse. Another one (Patient 10) received radiation therapy for his local bone relapse. All four of these patients achieved complete remission and survived. TRM occurred in one patient (7%) as a result of Epstein–Barr virus (EBV)-associated lymphoproliferative disorder (Patient 4). Seven patients survived and were free of disease between 30 and 159 months after transplantation (Table 2). With a median follow up of 36 months, the probability of 2-year EFS and the overall survival (OS) rate were 50% and 79%, respectively (Fig. 1).

### DISCUSSION

Seeking to achieve an optimal GVL effect on T-cells, in this study we investigated the technique of T-cell-replete haplo-SCT using a myeloablative preconditioning regimen accompanied by intensive GVHD prophylaxis in high-risk paediatric patients. It is important to focus on these patients because this patient population has a longer-term EFS of no more than 20%, despite our conventional allo-SCT and our chemotherapy protocols known to be efficacious (Einsiedel et al., 2005; Gaynon et al., 2006). The transplant regimen detailed in this study decreased the incidence of relapse, despite the patients’ advanced-stage leukaemia.

The outcome for patients who undergo haplo-SCT after myeloablative conditioning and standard GVHD prophylaxis is particularly dismal because they have the highest risk of graft rejection, aGVHD and, therefore, TRM (Powles et al., 1983; Beatty et al., 1985). Among BM transplants from partially HLA-identical sibling donors, the incidence of primary graft failure is 12.3%. For recipients from an HLA-identical sibling, the failure rate is only 2.0% (Anasetti et al., 1989). Several reports (Chang & Huang, 2012; Huang, 2008) detailed procedures for patients undergoing a haploidentical transplant with a more intensive in vivo GVHD prophylaxis. In patients receiving a T-cell-depleted graft, the rate of graft failure remains in the range of 0–17%, and the rate ranges of grades II–IV aGVHD, cGVHD and TRM are 8–48%, 0–35% and 28–65%, respectively. The graft failure rate among those receiving T-cell-replete grafts is in the range of 0–17%, and the incidence ranges of grades II–IV aGVHD, cGVHD and TRM are 16–66%, 13–53% and 9–35%, respectively.

### Table 1. Patient, donor and graft characteristics

| Patient | Age (year/sex) | Diagnosis | Cytogenetics | Status at SCT (time point of relapse) | Donor | HLA disparity in GVH | Stem cell source | CD34+ cells (×10^6 kg^{-1}) | CD34+ cells (×10^6 kg^{-1}) |
|---------|----------------|-----------|--------------|--------------------------------------|-------|----------------------|-----------------|-----------------------------|-----------------------------|
| 1       | 0.8/M          | ALL       | t(4;11)      | CR2 (VER)                            | Mother| 4/8                  | PB              | 11                          | NT                          |
| 2       | 1.8/F          | AML       |              | Refractory relapse after CBT         | Mother| 4/8                  | PB              | 10.49                       | 5.36                        |
| 3       | 7.7/M          | AML       |              | Refractory relapse                   | Father| 3/8                  | PB              | 8.43                        | 3.79                        |
| 4       | 12.0/M         | ALL       |              | Refractory relapse after BMT         | Father| 3/8                  | PB              | 13.2                        | 4.36                        |
| 5       | 11.9/F         | ALL       |              | Refractory relapse, MRD+ (ER)        | Father| 4/8                  | PB              | 11.5                        | 5.25                        |
| 6       | 6.8/M          | ALL       |              | CR2 (ER)                             | Father| 4/8                  | PB              | 8.32                        | 1.18                        |
| 7       | 6.0/M          | M/NK-AL   |              | Primary refractory                   | Father| 4/8                  | PB              | 13                          | 3.86                        |
| 8       | 5.0/M          | ALL       | t(9;22)      | Relapse after BMT, MRD+              | Mother| 3/8                  | PB              | 10                          | 5.51                        |
| 9       | 13.9/M         | ALL       |              | Refractory relapse after BMT         | Father| 4/8                  | PB              | 7.14                        | 2.74                        |
| 10      | 9.8/M          | ALL       | t(9;22)      | Relapse after BMT, MRD+              | Father| 4/8                  | PB              | 7.8                         | 5.22                        |
| 11      | 2.9/M          | ALL       |              | Refractory relapse (VER)             | Mother| 4/8                  | PB              | 5.65                        | 5.01                        |
| 12      | 13.8/M         | AMoL      | FLT3/ITD     | Primary refractory                   | Father| 4/8                  | PB              | 8.9                         | 5.84                        |
| 13      | 17.9/M         | M/NK-AL   | t(4;11)      | Primary refractory                   | Sibling| 4/8                 | PB              | 12.7                        | 3.71                        |
| 14      | 6.1/F          | ALL       | t(4;11)      | CR2, relapse after BMT               | Father| 3/8                  | PB              | 6.3                         | 1.83                        |

AMoL, acute monocytic leukaemia; BMT, bone marrow transplantation; CR2, second complete remission; CBT, cord blood transplantation; ER, early relapse at least 18 months after diagnosis but less than 6 months after cessation of chemotherapy; F, female; M, male; M/NK-AL, myeloid NK precursor acute leukaemia; NT, not tested; PB, peripheral blood stem cells; VER, very early relapse within 18 months after diagnosis.

Patients are sorted by the day of transplantation.
### Table 2. Stem cell transplantation and clinical outcome

| Patient | Conditioning regimen | Engraftment | Acute GVHD grade and stage (skin, liver, gut) | Chronic GVHD (affected organ) | Complications within 100 days | Outcome | Survival after SCT (days) | Cause of death | PS (%) |
|---------|----------------------|-------------|-----------------------------------------------|--------------------------------|------------------------------|---------|--------------------------|----------------|--------|
| 1       | TBI + CA + Mel       | Engraftment | Neut Plt                                     |                                |                              | CR      | 4783                     |                | 90     |
| 2       | TBI + CA + Mel       | 15          | 33 III (2, 0, 2)                              | Moderate (skin, lung, gut)     |                              | CR      | 3964                     |                | 90     |
| 3       | TBI + CY + CA* + ATG | 15          | 28 II (3, 0, 1)                               | Mild (gut)                     |                              | CR      | 1457                     |                | 90     |
| 4       | Bu2 + Flu + Mel + ATG| 15          | 34 I (1, 0, 0)                               | Mild (skin)                    |                              | NO      | Death                    |                | 439    |
| 5       | TBI + VP16 + CY + ATG| 12          | 22 II (3, 0, 0)                              | Mild (gut)                     |                              | CMV antigenemia | CR | 1393                     | EBV-LPD | –     |
| 6       | TBI + VP16 + CY + ATG| 11          | 93 II (3, 0, 0)                              | Mild (skin, gut)               |                              | CMV antigenemia | CR | 1198 (CR survival) | – | 90     |
| 7       | TBI + VP16 + CY + ATG| 14          | 28 II (3, 0, 0)                              | Mild (gut)                     |                              | CMV antigenemia, candida sepsis | CR | 1134 (CR survival) | – | 90     |
| 8       | Bu4 + Mel + ATG      | 13          | 18 I (1, 0, 0)                               | Mild (mucosa)                  |                              | CMV antigenemia, BKV-HC, zoster | CR | 1120 (CR survival) | – | 90     |
| 9       | Bu4 + CA + Mel + ATG | 13          | 35 II (3, 0, 0)                              | NE                             |                              | NO      | Relapse on day 117       |                | 549    |
| 10      | Bu4 + Flu + Mel + ATG| 12          | 21 II (3, 0, 0)                              | NO                             |                              | HC (RRT)| Relapse on day 600       |                | 1050 (CR survival) | – | 100   |
| 11      | TBI + VP16 + CY + ATG| 15          | 27 II (3, 0, 0)                              | Mild (eye)                     |                              | EBV-LPD, PRES, HHV6 | Relapse on day 405 |                | 993 (CR survival) | – | 90     |
| 12      | TBI + CY + CA* + ATG | 15          | NE 0                                        | NE                             |                              | NO      | Relapse on day 45        |                | 132    |
| 13      | TBI + VP16 + CY + ATG| 13          | 25 II (3, 0, 0)                              | Mild (gut)                     |                              | Klebsiella sepsis, CMV antigenemia | Relapse on day 159 |                | 952 (CR survival) | – | 90     |
| 14      | Bu4 + Flu + Mel + ATG| 11          | 75 III (2, 0, 3)                             | Mild (skin)                    |                              | BKV-HC, EBV-LPD, zoster | CR | 913 (CR survival) | – | 90     |

---

ATG, anti-human thymocyte immunoglobulin at 2.5 mg·kg\(^{-1}\); Bu2, busulfan at 8 mg·kg\(^{-1}\); Bu4, busulfan at 12–16 mg·kg\(^{-1}\); CA, cytarabine at 12 g·m\(^{-2}\); CA*, cytarabine at 12 g·m\(^{-2}\) combined with G-CSF; CR, complete remission; CMV, cytomegalovirus; CY, cyclophosphamide at 120 mg·kg\(^{-1}\); Flu, fludarabine at 150 mg·m\(^{-2}\); HC, hemorrhagic cystitis; Mel, melphalan at 140 mg·m\(^{-2}\); Neut, days to reach neutrophil count >0.5 × 10\(^9\) μL\(^{-1}\); NO, not observed; NE, not evaluated; PRES, posterior reversible encephalopathy syndrome; PS, performance status; Plt, days to reach platelet count >20 × 10\(^9\) μL\(^{-1}\); RRT, regimen-related toxicity; TBI, total-body-irradiation (12 Gy); TMA, thrombotic microangiopathy; VP16, VP16 at 1800 mg·m\(^{-2}\).
Fig. 1. Probability of OS and EFS. Kaplan–Meier estimates of OS and EFS in 14 patients who underwent T-cell-replete HLA-haploidentical SCT for advanced haematologic malignancies.

The conditioning treatment outlined in this present study, which includes low-dose ATG, demonstrated a satisfactory immunosuppressive effect. All the recipients achieved donor-type engraftments. On the basis of the data from the 14 patients we studied, we consider that the use of PBSCs containing a large number of T-cells (median: $4.36 \times 10^8$ CD3+ cells kg$^{-1}$ body weight) is also beneficial to obtain a high engraftment rate. In our study, 7% of patients (one patient) experienced TRM; this was associated with a viral infection. This risk seems to be acceptable, given the patient’s poor condition. However, severe immunosuppression resulted in the high risk of infectious complications. We treated these complications through early detection and treatment of infection, including pre-emptive treatment for cytomegalovirus viremia. We can decrease these infectious complications by using oral administration of BDP for gut GVHD patients instead of increasing general steroid administration. Frequent monitoring of EBV viral load by PCR and pre-emptive rituximab therapy may also reduce the risk of EBV-related lymphoproliferative disease (LPD) (Peric et al., 2011).

The first two patients we treated did not receive ATG, and one of them developed grade III GVHD. All subsequent patients received ATG, and one of them developed grade III GVHD. Neudorf et al. (2004) reported on the beneficial effects of grades I–II aGVHD, but also noted the detrimental effects of grades III–IV aGVHD in children with AML. The role of aGVHD in ALL has been less clearly defined than the generally accepted notion that the GVL effect plays an important role in the treatment of AML. Many recent publications (Zecca et al., 2002; Gustafsson Jernberg et al., 2003; Nordlander et al., 2004) have reported the effects of GVHD and GVL on remission rates and OS for acute leukaemic relapse after SCT in both adult and paediatric populations. This indicates that the GVL effect may also improve the ALL survival rate.

To achieve a partial T-cell-depletion of the graft, we used low-dose ATG (2.5 mg kg$^{-1}$ body weight). Although this low-dose ATG can result in high incidences of grade II aGVHD and cGVHD, these GVHDs are manageable with steroids. Temporary augmentation with PSL and the oral administration of BDP are effective treatments. This may be one of the possible reasons for our favourable outcomes.

Haploidentical transplantation is now possible with high sustained engraftment rates, low early post-transplantation mortality rates and low rates of severe GVHD, owing to recent advances in effective T-cell depletion techniques. Despite these successes, poor immune recovery and associated infectious complications leading to mortality and relapse remain major obstacles to overcome. Participants in our study had generally very poor prognoses, yet, with this new treatment protocol, the estimated probability of EFS at 2 years is about 50%. Despite the relatively high incidences of acute and chronic GVHD, our data are encouraging in terms of survival and TRM.

In conclusion, we have shown that T-cell-replete myeloablative haplo-SCT using a GVHD prophylactic regimen consisting of low-dose ATG, tacrolimus, MTX and PSL can reconstitute long-term haematopoiesis with acceptable incidences of treatment-resistant GVHD while preserving GVL effects in high-risk paediatric patients. A large-scale study, however, is needed to confirm these results more definitively.

ACKNOWLEDGMENTS

We wish to thank all the paediatricians and nurses who participated in the treatment and follow up of the patients in this study. A. K., M. I., H. S. and K. M. designed the research; A. K., M. L.,
H. S., K. M., M. A., S. K. T. W. and Y. O. collected the data; A. K. and S. K. analysed the data, interpreted the results and wrote the manuscript; M. H. and H. O. co-designed the experiments and discussed analyses and interpretation. All the authors discussed the results and commented on the manuscript.

**CONFLICT OF INTEREST**

The authors declare that there are no competing financial interests regarding this article.

**REFERENCES**

Anasetti, C., Amos, D., Beatty, P.G. et al. (1989) Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. *The New England Journal of Medicine*, 320, 197–204.

Aversa, F., Tabilio, A., Velardi, A. et al. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. *The New England Journal of Medicine*, 339, 1186–1193.

Aversa, F., Terenzi, A., Tabilio, A. et al. (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. *Journal of Clinical Oncology*, 23, 3447–3454.

Beatty, P.G., Clift, R.A., Mickelson, E.M. et al. (1985) Marrow transplantation from related donors other than HLA-identical siblings. *The New England Journal of Medicine*, 313, 765–771.

Chang, Y.J. & Huang, X.J. (2012) Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. *Current Opinion in Hematology*, 19, 454–461.

Einsiedel, H.G., von, Stackelberg, A., Hartmann, R. et al. (2005) Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. *Journal of Clinical Oncology*, 23, 7942–7950.

Gaynon, P.S. (2005) Childhood acute lymphoblastic leukaemia and relapse. *British Journal of Haematology*, 131, 579–587.

Gaynon, P.S., Harris, R.E., Altman, A.J. et al. (2006) Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. *Journal of Clinical Oncology*, 24, 3150–3156.

Gustafson Jernberg, A., Remberger, M., Ringdén, O. & Winiarski, J. (2003) Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. *Bone Marrow Transplantation*, 31, 175–181.

Henslee-Downey, P.J., Abhyankar, S.H., Parrish, R.S. et al. (1997) Use of partially mismatched related donors extends access to allogeneic marrow transplant. *Blood*, 89, 3864–3872.

Hijjya, N., Gajjar, A., Zhang, Z. et al. (2004) Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. *Leukemia*, 18, 1581–1586.

Huang, X.J. (2008) Current status of haploidentical stem cell transplantation for leukemia. *Journal of Hematology & Oncology*, 31, 1–27.

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. & Thun, M.J. (2008) Cancer statistics, 2008. *CA: A Cancer Journal for Clinicians*, 58, 71–96.

Kolb, H.J. (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. *Blood*, 112, 4371–4383.

McNeil, D.E., Cote, T.R., Clegg, L. & Mauer, A. (2002) SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. *Medical and Pediatric Oncology*, 39, 554–557.

Mehta, J., Singhal, S., Gee, A.P. et al. (2004) Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. *Bone Marrow Transplantation*, 33, 389–396.

Mochizuki, K., Kikuta, A., Ito, M., Sano, H., Akihata, M., Kobayashi, S., Ohito, H. & Hosoya, M. (2011) Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children. *Clinical Transplantation*, 25, 892–897.

Neudorf, S., Sanders, J., Kobrinsky, N. et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. *Blood*, 103, 3655–3661.

Nordlander, A., Mattsson, J., Ringdén, O. et al. (2004) Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. *Biology of Blood and Marrow Transplantation*, 10, 195–203.

Parker, C., Waters, R., Leighton, C. et al. (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. *The Lancet*, 376, 2009–2017.

Peric, Z., Cahu, X., Chevallier, P. et al. (2011) Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. *Leukemia*, 25, 932–938.

Powles, R.L., Morgenstern, G.R., Kay, H.E. et al. (1983) Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. *The Lancet*, 1, 612–615.

Raetz, E.A., Borowitz, M.J., Devidas, M. et al. (2008) Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study [corrected]. *Journal of Clinical Oncology*, 26, 3971–3978.

Sengsayadeth, S.M., Jagasia, M., Engelhardt, B.G. et al. (2012) Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. *Bone Marrow Transplantation*, 47, 1535–1537.

Suzuki, R., Suzumiya, I., Nakamura, S. et al. (2006) Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. *Bone Marrow Transplantation*, 37, 425–431.

Tallen, G., Ratei, R., Mann, G. et al. (2010) Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. *Journal of Clinical Oncology*, 28, 2339–2347.

Zecca, M., Prete, A., Rondelli, R. et al. (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. *Blood*, 100, 1192–1200.